Clinical medicine profile
Beclomethasone dipropionate nasal spray
Corticosteroid
- Route
- ORAL / IV / IM / INHALED / TOPICAL / NASAL / OPHTHALMIC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Systemic fungal infections (untreated) for systemic steroids.
- Live vaccines with significant immunosuppression.
- Hypersensitivity.
- Topical: untreated skin infection at site (relative).
Precautions
- Treatment of the infections of the
- nose and pharynx before using this medicine
- gradual withdrawal of exogenous steroids
- trans- fer of patients from systemic steroid treatment
- nasal trauma
- recent nasal surgery.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Fluid retention/hypertension — care in renal disease.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Prednisone needs hepatic activation to prednisolone.
Use, effects & interactions
Indications
- Prophylaxis and treatment of seasonal and perennial allergic rhinitis and hay fever Clinical selection for Beclomethasone dipropionate nasal spray should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Corticosteroid.
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Insomnia, increased appetite, mood lability, dyspepsia, hyperglycaemia.
- Chronic: cushingoid features, myopathy, osteoporosis, HPA suppression.
- Topical: skin atrophy, striae.
- Inhaled: thrush, dysphonia.
Drug interactions
Open multi-drug checker ↗- State indication and planned duration on every prescription.
- Bone protection if prolonged.
- Screen for strongyloides risk before prolonged high-dose in endemic exposure.
- ICS: spacer + rinse mouth.
Mechanism & disposition
Corticosteroids bind intracellular glucocorticoid receptors, modulating gene transcription to suppress inflammatory cytokines, inhibit phospholipase A2 via lipocortins, reduce leukocyte migration and stabilise membranes — potent anti-inflammatory and immunosuppressive effects.
Read complete mechanism
Corticosteroids bind intracellular glucocorticoid receptors, modulating gene transcription to suppress inflammatory cytokines, inhibit phospholipase A2 via lipocortins, reduce leukocyte migration and stabilise membranes — potent anti-inflammatory and immunosuppressive effects. Mineralocorticoid activity varies by agent.
Hours–days
Agent and route dependent
ORAL / IV / IM / INHALED / TOPICAL / NASAL / OPHTHALMIC
Pregnancy, lactation & diet
Used when maternal benefit clear; prefer agents with better obstetric data (e.g. prednisolone). Document risk–benefit.
Low-dose systemic often compatible; time feeds if high dose — agent-specific.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.